Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Amortizatization of Intangibles (2016 - 2026)

Neurocrine Biosciences filings provide 16 years of Amortizatization of Intangibles readings, the most recent being -$16.8 million for Q4 2025.

  • On a quarterly basis, Amortizatization of Intangibles fell 400.0% to -$16.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.1 million, a 84.35% decrease, with the full-year FY2025 number at $4.1 million, down 84.35% from a year prior.
  • Amortizatization of Intangibles hit -$16.8 million in Q4 2025 for Neurocrine Biosciences, down from $12.9 million in the prior quarter.
  • In the past five years, Amortizatization of Intangibles ranged from a high of $18.8 million in Q3 2024 to a low of -$16.8 million in Q4 2025.
  • Median Amortizatization of Intangibles over the past 5 years was $4.0 million (2021), compared with a mean of $2.9 million.
  • Biggest five-year swings in Amortizatization of Intangibles: skyrocketed 1160.0% in 2023 and later plummeted 400.0% in 2025.
  • Neurocrine Biosciences' Amortizatization of Intangibles stood at -$12.1 million in 2021, then surged by 104.13% to $500000.0 in 2022, then skyrocketed by 1160.0% to $6.3 million in 2023, then fell by 11.11% to $5.6 million in 2024, then plummeted by 400.0% to -$16.8 million in 2025.
  • The last three reported values for Amortizatization of Intangibles were -$16.8 million (Q4 2025), $12.9 million (Q3 2025), and $3.4 million (Q2 2025) per Business Quant data.